AstraZeneca AB Patent Application Trends in 2025
AstraZeneca AB Patent Filing Activity
AstraZeneca AB patent applications in 2025
Top 10 Technology Areas
- C07K16/2866 (PEPTIDES (peptides in foodstuffs)
- Count: 5 patents
- Example: 20250002589. TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOUS (ASTRAZENECA AB)
- A61K2039/505 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 5 patents
- Example: 20250002589. TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOUS (ASTRAZENECA AB)
- A61K2039/545 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 4 patents
- Example: 20250002589. TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOUS (ASTRAZENECA AB)
- C12N15/113 (Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants)
- A61K31/4184 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 3 patents
- Example: 20250000848. PHARMACEUTICAL COMPOSITION (ASTRAZENECA AB)
- A61P37/06 (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS)
- Count: 3 patents
- Example: 20250002589. TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOUS (ASTRAZENECA AB)
- A61K45/06 (Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca)
- A61P35/00 (Antineoplastic agents)
- Count: 3 patents
- Example: 20250057969. CONJUGATES COMPRISING CLEAVABLE LINKERS (AstraZeneca AB)
- C12N2310/14 (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media)
- Count: 2 patents
- Example: 20250064944. MULTIVALENT CARGO-CARRYING COMPLEXES AND USES THEREOF (ASTRAZENECA AB)
- C07D405/14 (HETEROCYCLIC COMPOUNDS (macromolecular compounds)
- Count: 2 patents
- Example: [[20250066338. CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS (AstraZeneca AB)]]
Emerging Technology Areas
- C07K2317/76 (PEPTIDES (peptides in foodstuffs)
- Count: 1 patents
- Example: 20250101116. ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY (ASTRAZENECA AB)
- C07K2317/734 (PEPTIDES (peptides in foodstuffs)
- Count: 1 patents
- Example: 20250101116. ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY (ASTRAZENECA AB)
- C07K2317/732 (PEPTIDES (peptides in foodstuffs)
- Count: 1 patents
- Example: 20250101116. ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY (ASTRAZENECA AB)
- C07K2317/71 (PEPTIDES (peptides in foodstuffs)
- Count: 1 patents
- Example: 20250101116. ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY (ASTRAZENECA AB)
- C07K2317/24 (PEPTIDES (peptides in foodstuffs)
- Count: 1 patents
- Example: 20250101116. ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY (ASTRAZENECA AB)
- C07K2299/00 (PEPTIDES (peptides in foodstuffs)
- Count: 1 patents
- Example: 20250101116. ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY (ASTRAZENECA AB)
- A61K31/513 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 1 patents
- Example: 20250099580. TREATMENT OF GASTRIC CANCER AND/OR GASTROESOPHAGEAL JUNCTION CANCER (AstraZeneca AB)
- A61K31/337 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 1 patents
- Example: 20250099580. TREATMENT OF GASTRIC CANCER AND/OR GASTROESOPHAGEAL JUNCTION CANCER (AstraZeneca AB)
- A61K31/282 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 1 patents
- Example: 20250099580. TREATMENT OF GASTRIC CANCER AND/OR GASTROESOPHAGEAL JUNCTION CANCER (AstraZeneca AB)
- A61K39/3955 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms)
- Count: 1 patents
- Example: 20250099580. TREATMENT OF GASTRIC CANCER AND/OR GASTROESOPHAGEAL JUNCTION CANCER (AstraZeneca AB)
Top Inventors
- RAJENDRA TUMMALA of WILMINGTON DE (US) (3 patents)
- Lars Anders DAHLÉN (2 patents)
- Magnus POLLA (2 patents)
- Joakim BERGMAN (2 patents)
- Johan SUNDELL (2 patents)
- Jonas BRÅNALT (2 patents)
- Johan KAJANUS (2 patents)
- Ekaterina RATKOVA (2 patents)
- Magnus JOHANSSON (2 patents)
- CATHARINA LINDHOLM (2 patents)
Patent Categories
Geographical Distribution of Inventors
Geographical Distribution of US Inventors
Categories:
- AstraZeneca AB
- Companies
- CPC C12N15/113
- CPC C12N9/22
- CPC C12N15/102
- CPC C12N2310/20
- CPC C12N2800/22
- CPC C12N2800/24
- CPC C12N2810/40
- CPC A61K47/549
- CPC A61K47/548
- CPC C12N2310/11
- CPC C12N2310/14
- CPC C12N2310/3511
- CPC C07D405/14
- CPC A61K31/4439
- CPC A61K31/4184
- CPC A61K9/0053
- CPC A61K9/145
- CPC A61K9/146
- CPC A61K9/4858
- CPC A61K9/4866
- CPC A61K47/22
- CPC A61K47/36
- CPC C07D235/06
- CPC C07K16/2866
- CPC A61K9/0019
- CPC A61K47/183
- CPC A61P37/06
- CPC A61K2039/505
- CPC A61K2039/54
- CPC A61K2039/545
- CPC A61P13/12
- CPC G01N33/6893
- CPC C07K2317/565
- CPC G01N2333/775
- CPC G01N2333/79
- CPC A61K31/573
- CPC A61K45/06
- CPC A61K39/155
- CPC A61K9/127
- CPC A61K9/5123
- CPC A61P31/14
- CPC C12N7/00
- CPC A61K2039/53
- CPC A61K2039/55555
- CPC C12N2760/18534
- CPC C12N2760/18551
- CPC A61K31/506
- CPC A61K9/2054
- CPC A61K9/28
- CPC A61K47/545
- CPC A61K47/6851
- CPC A61K9/124
- CPC A61K9/008
- CPC A61K31/137
- CPC A61K31/167
- CPC A61K31/40
- CPC A61K31/44
- CPC A61K31/58
- CPC A61K47/06
- CPC A61K47/24
- CPC A61K47/68031
- CPC A61K47/6849
- CPC A61K47/6855
- CPC A61K47/6889
- CPC A61P35/00
- CPC A61K31/498
- CPC A61K31/336
- CPC A61K31/4188
- CPC A61K41/0038
- CPC A61N5/00
- CPC A61K31/4458
- CPC A61K31/517
- CPC A61K31/519
- CPC A61K31/5377
- CPC A61K31/553
- CPC A61K9/2009
- CPC A61K9/2013
- CPC A61K9/2059
- CPC A61K31/675
- CPC C07K16/241
- CPC C07K16/2887
- CPC A61K31/70
- CPC A61P3/10
- CPC A61P9/12
- CPC A61K31/635
- CPC A61K31/706
- CPC A61K47/68037
- CPC A61P35/02
- CPC C07K2317/569
- CPC C07K2317/622
- CPC C12N2310/351
- CPC C12N2310/51
- CPC C07D413/06
- CPC C07D271/06
- CPC C07D409/06
- CPC C07D413/04
- CPC C07D413/12
- CPC C07D413/14
- CPC C07D471/04
- CPC C07D487/04
- CPC C07D498/10
- CPC A61K39/3955
- CPC A61K31/282
- CPC A61K31/337
- CPC A61K31/513
- CPC C07K2299/00
- CPC C07K2317/24
- CPC C07K2317/71
- CPC C07K2317/732
- CPC C07K2317/734
- CPC C07K2317/76
- Patent Trends by Company in 2025
